Skip to main content
U.S. flag

An official website of the United States government

Return to Search

NaF-18 PET for Bone Metastasis

Guidance for specific clinical indications under which CMS will cover NaF-18 Positron Emission Tomography (NaF-18 PET). The NCD concluded that NaF-18 PET scans are reasonable and necessary under Section 1862(a)(1)(E) of the Social Security Act in the context of Coverage with Evidence Development (CED).

Final

Issued by: Centers for Medicare & Medicaid Services (CMS)

Issue Date: March 05, 2020

This national coverage determination (NCD) was issued on February 26, 2010.  It establishes specific clinical indications under which CMS will cover NaF-18 Positron Emission Tomography (NaF-18 PET).  The NCD concluded that NaF-18 PET scans are reasonable and necessary under Section 1862(a)(1)(E) of the Social Security Act in the context of Coverage with Evidence Development (CED).

Prospectively under CED, NaF-18 PET imaging must lead to:

  • A change in patient management to more appropriate palliative care; or
  • A change in patient management to more appropriate curative care, or
  • Improved quality of life; or
  • Improved survival

The clinical research study also must adhere to certain standards of scientific integrity and relevance to the Medicare population.

Decision Memos

 

On its website, CMS will maintain a list of all approved studies and facility locations on its website. A list of facility locations can be found here: /MedicareApprovedFacilitie/NOPR/list.asp#TopOfPage

Registry Approvals:

Study Title: The National Oncologic PET Registry (NOPR)
Sponsor: American College of Radiology Imaging Network
ClinicalTrials.gov Number: NCT00868582
CMS Approval Date: 2/26/2010
Enrollment closed 12/14/2017

HHS is committed to making its websites and documents accessible to the widest possible audience, including individuals with disabilities. We are in the process of retroactively making some documents accessible. If you need assistance accessing an accessible version of this document, please reach out to the guidance@hhs.gov.

DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.